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Abstract 
The fully de novo design of protein building blocks for self-assembling as functional 
nanoparticles is a challenging task in emerging nanomedicines, which urgently demand 
novel, versatile and biologically safe vehicles for imaging, drug delivery and gene 
therapy. While the use of viruses and virus-like particles is limited by severe 
constraints, the generation of protein-only nanocarriers is progressively reachable by 
the engineering of protein-protein interactions, resulting into self-assembling functional 
building blocks. In particular, end-terminal cationic peptides drive the organization of 
structurally diverse protein species as regular nanosized oligomers, offering promise in 
the rational engineering of protein self-assembling. However, the in vivo stability of 
these constructs, being a critical issue for their medical applicability, needs to be 
assessed. We have explored here if the cross-molecular contacts between protein 
monomers, generated by end-terminal cationic peptides and oligohistidine tags, are 
stable enough for the resulting nanoparticles to overcome biological barriers in 
assembled form. The analyses of renal clearance and biodistribution of several tagged 
modular proteins reveal long-term architectonic stability, allowing systemic circulation 
and tissue targeting in form of nanoparticulate material. This observation fully supports 
the value of the engineered of protein building blocks addressed to the biofabrication of 
smart, robust and multifunctional nanoparticles with medical applicability, that mimic 
structure and functional capabilities of viral capsids.  
 
 
Nanoparticles; Self-assembling; Architectonic stability; Protein folding; Artificial viruses; 
Biodistribution
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Different types of materials are under examination for the construction of nanoparticles 
as molecular carriers in diagnosis and therapy, including lipids, diverse types of 
polymers, dendrimers, carbon nanotubes and metals. 1 While the usage of many of 
these candidates is technically appealing and their manufacture economically feasible, 
biocompatibility issues severely compromise in vivo applicability. 2 Instead, proteins are 
ideal biomaterials for therapeutic applications, because of their natural structural roles, 
easy and cost-effective biological production, functional tuneability by genetic 
engineering and full biocompatibility. Regarding drug delivery, several categories of 
entities found in nature support the concept of proteins as ideal nano- or micro-cages 
for molecular carriage. Infectious viruses, 3,4 virus-like particles (VLPs) 5 and more 
recently bacterial microcompartments (BMC) 6 and eukaryotic vaults 7 are being 
explored to transport and deliver nucleic acids, peptides or proteins, chemicals, metals 
and quantum dots, among others. However, biosafety concerns in the case of viruses 
and narrow flexibility in re-adapting tropism and geometry in VLPs, vaults and BMCs, 
stress the need of novel protein nanocages that being highly tuneable and functionally 
versatile, would not be limited by the above constraints.  
 
The highly organized protein shells of viruses and other natural protein nanocages are 
formed by self-assembling building blocks that interact through a complex combination 
of electrostatic, hydrophobic, van der Waals and hydrogen bond forces. 8 So far, the de 
novo design of self-assembling protein monomers for tailored construction has poorly 
advanced and it is reluctant to generic rational design. 9 Self-assembling amyloidogenic 
peptides, although showing a wide spectrum of applications in nanomedicine, 9 are 
unable to generate regular sized shells for controlled drug encapsulation, and their 
biological fabrication poses important challenges. Concerning full proteins, a limited 
number of engineering approaches have rendered self-organizing cages or filaments, 
by adapting oligomerization domains from natural oligomeric proteins, 10,11,12,13 through 
the in silico-assisted fine engineering of protein-protein interfaces 14 or by designing 
disulfide bonds between cysteine-carrying modified stretches. 15  
 
Recently 16, we have described a new protein engineering principle for the construction 
of self-assembling, protein-only nanoparticles, based on the combined use of one 
cationic peptide plus a polyhistidine. These peptides, fused at either the end termini of 
recombinant proteins confer tagged monomers (structurally different protein species 
such as GFP and p53) with a strong dipolar charge distribution that supports 
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spontaneous self-organization as monodisperse nanoparticulate materials. The size of 
these particles can be regulated by the ionic strength and specially, by the composition 
in the cationic residues of the N-terminal tag (larger particle size when tails contain 
more cationic residues, under a lineal dependence). 16 The N-terminal peptide acts, in 
addition, as a cell-receptor specific ligand that confers targeting properties to the 
particle. 16 The relevance of this engineering principle relies on its generic applicability, 
since contrarily to other proposed approaches it is not limited to any particular protein 
species and it does not require precise amino acid stretches or composition in the 
building block to ensure proper assembly, as potentially, any protein can be tagged to 
promote self-organization. These peptide-driven nanoparticles have been proved 
useful for the targeted intracellular delivery of proteins 17 and expressible DNA, 18 so far 
in absence of detectable cellular or organic toxicity. 19  
 
In particular, the modular protein T22-GFP-H6 was constructed under such tag-based 
principle, and it forms regular, 13 nm-nanoparticles that internalize, in a particulate 
form, in CXCR4-expressing cells (T22 being a peptidic ligand of CXCR4 20). 19 When 
administered in metastatic colorectal cancer animal models in which CXCR4 
overexpression is clinically relevant, T22-GFP-H6 shows an excellent biodistribution 
and it is internalized by CXCR4+ cells in the primary tumor and also in the metastatic 
foci. 16 While this fact is highly promising regarding medical applicability of this platform, 
it is not clear whether the intermolecular interactions promoted by these nano-
architectonic peptides are strong enough to ensure the stability of nanoparticles in vivo. 
In fact, the occurrence of T22-GFP-H6 in target cells and tissues determined by 
immunohistochemistry does not ensure that the nanoparticulate structure has been 
maintained during in vivo administration. The in vivo stability of the nanoparticle formed 
in vitro needs to be confirmed in order to implement this platform as a generic tool for 
drug design. In fact, if the protein-protein interactions promoted by the peptidic tags are 
weaker and less complex than those supporting assembling of infectious viruses, 
VLPs, vaults and BMC shells, it could be not ruled out that the nanoparticles formed in 
vitro by artificial monomers would be immediately disassembled once administered, as 
the blood stream and intracellular media are rich in charged molecules. In this context, 
limited stability and a premature release of cargo drugs or imaging agents would fully 
invalidate the system for further development.  
 
In this regard, determining if a multifunctional protein reaches its target tissue in a 
nanoparticulate form or as disassembled monomers is not easily approachable 
experimentally. The a priori choice transmission electron microscopy (TEM) does not 
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offer enough resolution to discriminate between monomeric and nanoparticulate forms 
(~6 nm versus ~13 nm) of protein materials inside target cells (a complex and 
heterogeneous protein-rich media with similar electrodensity than recombinant 
proteins), and also between internalized and endogenous protein structures within this 
size range. Antibodies and gold nanoparticles used in immunolabelling techniques for 
TEM are also within the same size range. Therefore, we have determined here the in 
vivo architectonic stability of the novo designed protein nanoparticles (and therefore, 
the validity of the whole architectonic principle) by an approach alternative to direct 
TEM observation that permits a rapid and feasible in vivo translation and a refined 
analysis at the whole body level. This is based on the monitoring of renal clearance 
and biodistribution of several reporter building blocks (constructs R9-GFP-H6, T22-
GPP-H6, T22-IRFP-H6) administered as either monomers (< 7 nm) or assembled 
entities (> 7 nm). Parental monomeric species as well as closely related protein 
variants that do not form nanoparticles have been also used as controls. As renal 
filtration occurs for compounds with a size lower or around 7 nm,  21 accumulation of 
the administered material in kidney but not in target tissues would be indicative of 
disassembling, while occurrence in target tissues but not in kidney would prove the in 
vivo stability of nanoparticles. Interestingly, the obtained results indicate that 
nanoparticles formed in vitro are highly stable during systemic circulation, thus proving 
the structural robustness and strong potential of end terminal cationic tags as nano-
architectonic tools for medical applications. 
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Results and discussion 
The fusion of N-terminal cationic peptides to H6-tagged GFP promotes the self-
organization of the construct into protein-only nanoparticles of sizes ranging from 10 to 
50 nm. 16 These particles are immediately observed upon protein purification from 
recombinant bacteria and they probably assemble in the storage buffer against which 
the protein is dialyzed after elution. Being highly cationic, peptides R9 and T22 (used in 
nanomedicine for brain targeting and CXCR4+ cell targeting respectively, Figure 1 A) 
support the self-assembling of GFP-H6 as fully fluorescent particles of ~20 nm and ~13 
nm (Figure 1 B). The sizes of these particles, primarily determined by DLS, were 
confirmed by TEM (Figure 1 C) and AFM (Figure 1 D, and Supplementary Figures 1 
and 2). In contrast, the non-cationic peptides Ang-and Seq fail in promoting any 
supramolecular organization of the fusion proteins, and the size of the monomers was 
coincident in both cases with that of GFP-H6 (around 6 nm, Figure 1 B).  
 
In mice, upon single intravenous (i.v.) administration at equal doses, Ang-GFP-H6, 
Seq-GFP-H6 and the parental GFP-H6 accumulated in kidney (Figure 2 A, B, C), 
indicative of renal clearance and in agreement with the occurrence of these proteins in 
a monomeric form also in vivo. Contrarily, R9-GFP-H6 and T22-GFP-H6 were not 
observed in kidney (Figure 2 A, B, C), suggesting that the nanoparticulate architecture 
reached by these proteins in vitro (Figure 1 C, D) was maintained in vivo during 
circulation in blood. No protein was detected in lung, heart, spleen or liver in any case 
(Figure 2 A). Consistently with their lack of renal clearance the fluorescence emitted by  
R9-GFP-H6 and T22-GFP-H6 was detectable in plasma showing a first fast half-life of 
rapid distribution in the blood compartment, followed by a second and slow half-life of 
long-lasting permanence in blood (Figure 2 D, and Supplementary Table 1). 
Leucocytes and platelets showed lack of fluorescence accumulation for R9-GFP-H6, 
whereas fluorescence after T22-GFP-H6 administration was slightly increased in these 
blood cells as compared to background fluorescence in non-accumulating tissues, but 
it was till 100 times lower than fluoresce reached by T22-GFP-H6 in tumor tissue.  No 
accumulation was observed in red blood cells (Supplementary Figure 3). Although a 
priori it could be not discarded that the absence of protein in kidney would be due to a 
proteolytic instability and fast degradation, T22-GFP-H6 was observed to be highly 
stable in plasma and when administered to colorectal cancer mice models it 
accumulated in primary tumors and metastatic foci. 19 The combination of all these data 
was indicative that the protein reached its target in a full-length form. In this particular 
construct, the N-terminal peptide T22 was at the same time an architectonic tag and a 
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cell-specific ligand, as it binds the cell surface receptor CXCR4 and internalizes 
CXCR4+ cells. 19,20 Interestingly, no enhancement of apoptosis was observed in any of 
the checked organs, namely non-tumoral lung, heart, spleen and liver (Supplementary 
Figure 4), and no loss of weight or other pathological signs of toxicity were observed in 
any of the administered animals as compared to vehicle-treated animals (not shown). 
The absence of cellular toxicity of T22-GFP-H6 in vitro had been already reported, 19 
altogether indicating a potential of these protein particles for in vivo applications.  
 
To complement these data, we first confirmed the proteolytic stability of R9-GFP-H6 
and related monomeric proteins in plasma and serum (Figure 3 A), that was as high as 
that observed in T22-GFP-H6. 19 Then, the biodistribution analysis of R9-GFP-H6 upon 
administration determined that this protein nanoparticles localized in brain (a 
background occurrence of GFP-H6 was also determined; Figure 3 B, C). This was not 
completely unexpected as previous findings suggested a BBB-crossing potential of R9 
and related arginine rich peptides. 22,23 Since neither R9- nor T22-empowered proteins 
were detected in lung or heart (Figure 2 A), the possibility of unspecific protein 
aggregation can be strongly excluded, whereas the lack of accumulation in spleen or 
liver indicate that they are not taken by the mononuclear phagocyte system that affects 
other categories of nanoparticles. 24,25 Again, the absence of these proteins in kidney 
must be exclusively attributed to their nanoparticulate organization that prevents size-
dependent clearance. Renal filtration of parental GFP-H6 and related non-assembling 
proteins also indicated that these constructs, with a size very close to the threshold for 
filtration, do not tend to aggregate or assemble in vivo and that they keep their 
monomeric form during circulation in blood.  
 
While offering an enormous potential in the design of artificial viruses and protein 
nanoparticles for medical purposes, 26 the high in vivo architectonic stability of R9-GFP-
H6 and T22-GFP-H6 observed here was not anticipated. Being R9 and T22 highly 
cationic and the whole chimerical constructs showing a dipolar charge distribution 16 we 
expected electrostatic charges being the main drivers of protein assembly. Then, 
nanoparticle stability in media with a high load of charged components, such as 
bloodstream (negatively charged proteins and a wide catalogue of ions) was at least 
initially surprising, as we could presume molecular competitions between charged 
agents and building blocks and consequent particle dissociation. Experimental data 
indicated, instead, that nanoparticles formed in vitro keep such organization also in 
vivo. To test this ‘structural memory’ we evaluated renal clearance of a novel modular 
protein generated in this study (T22-IRFP-H6). In this construct, the core of the building 
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block is iRFP, a dimeric fluorescent protein with primary sequence and structure 
unrelated to those of GFP. Once purified in low salt buffer, this construct self-organizes 
as nanoparticles of ~14 nm (Figure 4 A, B) while it remains disassembled (probably as 
natural dimers) in high salt buffer (Figure 4 A). Furthermore, adding salt to the protein 
when already assembled in low salt buffer (to reach the same salt concentration than in 
high salt buffer) does not alter particle size (Figure 4 C). This is indicative of a tight 
organization of the protein assemblies and of robust cross-molecular interactions 
between monomers that are not responsive to alterations of the media conditions upon 
assembling. In this context, NP40 had also no effect on the stability of nanoparticles 
(Figure 4 D) while the strong denaturant detergent SDS used as a control 
disassembled the constructs already at 0.1 % (Figure 4 E). The progressive reduction 
of the protein size observed at 0.1 and 1 % could reflect a hierarchical disassembly of 
nanoparticles first releasing dimeric T22-IRFP-H6 building blocks and later individual 
denatured monomers. 
 
To assess more robustly the in vivo stability and architectonic memory of protein 
nanoparticles we administered the polypeptide T22-IRFP-H6 to colorectal cancer mice 
models, either in disassembled (high salt buffer) or assembled (low salt buffer) forms. 
Upon i.v. injection, renal clearance was observed only in the case of the disassembled 
protein, while tumor targeting was only observed in the nanoparticulate form (Figure 5 
A, B). This fact indicated again the preservation in the bloodstream of the molecular 
organization adopted in vitro, but also it proved that tissue targeting by efficient cell 
surface ligands is impaired by renal clearance, as it prevents individual proteins 
reaching the intended target. Presentation of the failing polypeptide in a nanostructured 
form with a size higher than 7 nm instead avoids renal excretion and it confers a high 
recirculation time in blood, thus offering opportunities for its accumulation in the target 
tissue. Importantly, since the cell ligand is the peptide T22 in both cases, no biased 
biodistribution could be potentially attributed to the use of different ligands but 
exclusively to the presentation in disassembled or assembled forms.   
 
To explore the fine architecture of these nanoparticles we fist estimated the number of 
monomers forming them, by size-exclusion chromatography. Interestingly, the 23 nm 
R9-GFP-H6 particles peaked out of the column range, but still, an important fraction 
peaked at a value compatible with a pentameric organization of the protein, in 
agreement with previous in silico modeling. 16,18,19 There, the basic structure of R9-
GFP-H6 nanoparticles has been suggested to be star-shaped discoidal pentamers, in 
which monomers are organized as a ring around an empty center. 18 On the other 
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hand, T22-GFP-H6 and T22-IRFP-H6 were majorly organized in clusters of ten 
monomers (Figure 6 A), but minor peaks corresponding to fifteen T22-IRFP-H6 
monomers, to the T22-IRFP-H6 dimer (the natural form of IRFP) and to T22-GFP-H6 
monomers were also observed. The occurrence of oligomers formed at least by five, 
ten and fifteen monomers would account for the slight polydispersion of the particle 
size determined by DLS (Figure 1 B) and strongly suggested the stacking of basic 
pentameric blocks in higher order structures. In this regard, the tubular organization 
observed in R9-GFP-H6-DNA complexes 27 is again fitting with a model in which 
nanodisks are piled as cylinders. The robustness of the emission spectra of assembled 
GFP variants when compared with regular GFP (Figure 6 B) indicated little or no 
conformational changes in the GFP barrel associated to nanoparticle formation. In this 
context, the overhanging tails (R9 or T22 and H6) rather than the monomer core itself 
could be the main responsible for protein-protein interactions in the nanoparticle, as 
previously suggested. 16,18 In a last structural analysis, Cryo-TEM and especially high 
resolution FESEM (Figure 6 C) showed a ring shaped organization of all protein 
particles that in the case of T22-GFP-H6, would be compatible with two staked 
pentamers. These new data confirmed again the particle sizes determined primarily by 
DLS and AFM (Figure 1 and Supplementary Figure 1 and 2) and the circular 
distribution of the protein material (Figure 6 C). 
 
All these results clearly indicate that once nanoparticles are formed, their architecture 
remains stable both in vitro and in vivo, and that while salt content modulates the initial 
configuration of protein-protein interactions it does not disturb the structure of the 
formed supramolecular complexes. The cross-molecular contacts between monomers 
would be then more complex than mere electrostatic interactions and probably similar 
to those occurring in viruses and related entities. At a neutral pH, the poly-histidine tail 
is not charged, and the interaction between arginines and neutral histidines is known to 
be strong, as it may combine polar, hydrophobic and cation-pi (between the 
guanidinium positive charge and the aromatic imidazole ring) interactions. These 
interactions may be favorable even when H6 is positively charged, as expected under 
slightly acidic environments. 28,29  
 
Because of the especially high definition of ring-shaped FESEM images and the 
occurrence of pentameric structures in R9-GFP-H6 nanoparticles, we modeled protein-
protein interactions in this particular construct 16,18. Different probable star-shaped 
nanoparticles resulted from the docking process depending on the conformation 
adopted by the overhanging end terminal peptides, all of them in the range of 15-30 nm 
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and compatible with the nanoparticle size (Figure 7). When resolving the energetics 
organizing the monomers, complex combinations of electrostatic interactions, van der 
Waals forces and hydrogen bonds were found in all cases (Table 1), as in those 
occurring in natural protein complexes. 30 The strong weight of van der Waals forces 
and hydrogen bonds revealed that electrostatic contacts, although important, were not 
the unique actors in the self-assembling of modular monomers. In this context, capsid 
proteins interact mainly through a combination of electrostatic repulsion, hydrophobic 
attraction and specific contacts between given pairs of amino acids. These interactions 
impose a certain restriction in the orientation of the interaction during complex 
formation, and once this is formed the weaker van der Waals forces complete the 
assembly. Varying the acidity and salinity conditions (or the concentration of Ca2+ ions) 
adjusts the relative balance between these competing interactions, thereby favouring 
assembly or disassembly. Electrostatic contacts might be the starting force promoting 
initial protein-protein contacts in artificial protein nanoparticles, which are later 
complemented with other type of interactions by slight conformational/spatial 
adjustments. 
 
Linked to their high functional versatility, proteins (in form of ligands or antibodies) are 
preferred to functionalize most of the currently developed drug vehicles targeted to 
specific cell types. 31  In addition, because of the high protein biocompatibility and 
versatility offered by genetic engineering, protein-only nanoparticles are extremely 
promising in nanomedicine as they can recruit, apart from cell targeting, a diversity of 
functions that are appealing in drug delivery such as self-assembling, cage formation, 
nucleic acid binding, endosomal escape and nuclear transport. 32,33,34 The less desired 
immunogenicity associated to proteins is expected to be solved by using homologous 
and biologically inert proteins (such as albumin) as scaffolds for nanoparticle 
construction. 35 However, protein self-assembling is far from full rational control. This is 
due to the current inability in linking molecular architecture with the forces that regulate 
cross-molecular interactions. 30 In fact, the actual complexity that allows correct 
assembling of viral shells is not reflected by the apparent simplicity of the capsid 
components and it cannot be predicted in advance from the analysis of the monomers. 
Here we prove that the assembly promoted by a short cationic peptide (such as R9 or 
T22) combined with a hexahistidine tail, fused to the end termini of different proteins 
acting as building blocks, mimic the organization of natural protein complexes such as 
viral shells, conferring a high stability of the nanoparticle once administered in the 
bloodstream. Importantly, the efficient tissue targeting combined with absence of renal 
filtration indicates that R9 and T22 peptides maintain their activities as ligands while 
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promoting the cross-molecular interactions between monomers in tightly assembled 
nanoparticles. In the particular case of T22, its targeting to CXCR4+ cells makes this 
tag not only appealing for drug delivery in colorectal cancer but also in the treatment of 
other neoplasias (e.g. breast, ovary or prostate cancer or acute myeloid leukaemia),36 
in which high membrane expression of CXCR4 correlates with poor prognosis. Protein 
nanoparticles displaying effective T22 tags could also be used as vehicles for targeting 
other diseases in which the pathological mechanisms involve CXCR4 expression, such 
as pulmonary fibrosis 37 or myocardial infarction. 38   
 
 Since the tags tested here promote self-assembling of structurally diverse proteins 
such as GFP, 16 p53 16 and iRFP (the present study), it opens a plethora of 
opportunities in selecting monomer cores that could be more convenient to avoid 
immune responses (namely homologous proteins) when administering protein 
nanoparticles in a clinical context. On the other side, proteins such as p53 with an 
intrinsic therapeutic value might gain stability and therefore activity when delivered with 
a particulate organization, in a step beyond the purpose of acting as mere carriers for 
the delivery of cargo drugs. Although ionic strength appears to be important during 
nanoparticle organization, this parameter does not affect the stability of already formed 
particles. This fact allows these entities overcoming biological barriers and reaching 
their target in a nanoparticulate form. The engineering platform based on the addition 
of architectonic tags other than oligomerization domains offer a wide and unexpected 
plasticity in the design of multifunctional modular monomers (a diversity of protein 
species being suitable as cores), and it opens a spectrum of opportunities for the fully 
de novo design of robust protein-based carriers (artificial viruses) for emerging 
nanomedical applications. 
 
Conclusions 
We have here determined the functional robustness and architectonic stability of fully 
de novo designed protein-only nanoparticles, based on a generic engineering principle 
in which modular monomers are tagged with end-terminal cationic peptides. A sharp 
coincidence between nanoparticle formation in vitro and the in vivo escape from renal 
filtration has been revealed for several model proteins, proving the maintenance of 
protein-protein interactions in the bloodstream. Then, the architectonic principles 
described here offer promise to approach a rational design of self-assembling artificial 
viruses based on recombinant proteins for nanomedical applications in vivo. 
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Methods 
Proteins and protein purification 
R9-GFP-H6 and T22-GFP-H6 are modular proteins in which the cationic peptides R9 
(nine arginines, 23) and T22 (derived from polyphemusin II, 20) are respectively fused to 
the amino terminus of a hexahistine C-tagged GFP (GFP-H6). These peptides, apart 
from providing positive charges that create a dipolar building block,19 confer targeting 
properties to the resulting nanoparticle. In the case of T22, a ligand of CXCR4,20 this 
has been experimentally confirmed as the administered protein accumulates in primary 
and metastatic foci in a colorectal cancer model.19 Ang-GFP-H6 and Seq-GFP-H6 are 
closely related proteins that do not form nanoparticles, since the amino-terminal tags 
are not cationic.19 T22-IRFP-H6 was designed in house, and synthetic genes were 
provided and subcloned into pET22b plasmid vector (using NdeI and HindIII restriction 
sites) by Genesript (Piscataway, USA). T22-IRFP-H6 has a similar modular scheme 
than T22-GFP-H6 but in this case, the central part of the fusion was not GFP but the 
near-infrared fluorescent dimeric protein IRFP. 39 All proteins were encoded by pET22b 
in Escherichia coli Origami B (BL21, OmpT-, Lon-, TrxB, Gor- (Novagen)), produced 
overnight at 20 Cº upon 1 mM IPTG addition, and purified by Histidine-tag affinity 
chromatography as described.16 In short, we used HiTrap Chelating HP 1 ml columns 
(GE Healthcare) in an ÄKTA purifier FPLC (GE Healthcare). Cell extracts were 
disrupted at 1100 psi in a French Press (Thermo FA-078A) and soluble and insoluble 
fractions separated by centrifugation at 20,000 g for 45 min at 4ºC. The soluble fraction 
was charged onto HiTrap column and subsequently washed with Tris 20 mM, NaCl 500 
mM, Imidazole 10 mM, pH=8 buffer. Proteins were eluted by linear gradient of high 
Imidazole concentration buffer (20 mM Tris, 500 mM NaCl, 500 mM Imidazole, pH=8). 
Once in elution buffer, they were dialyzed against the most appropriate buffer regarding 
stability (empirically determined to minimize unspecific aggregation), which was found 
to be carbonate buffer (166 mM NaHCO3, pH 7.4) for Ang-GFP-H6, Seq-GFP-H6 and 
T22-IRFP-H6, Tris NaCl (20 mM Tris, 500 mM NaCl pH 7.4) for T22-GFP-H6 and Tris 
dextrose (20 mM Tris, 5 % dextrose pH 7.4) for GFP-H6 and R9-GFP-H6. The high salt 
buffer was always obtained by adding NaCl to reach a final concentration of 500 mM. 
Once dialyzed, protein samples were stored at -80 ºC until use. Protein integrity was 
systematically assessed by Western blot analysis, MALDI-TOF and N-terminal 
sequencing. 
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Analysis of protein stability 
The stability of proteins GFP-H6, R9-GFP-H6, Ang-GFP-H6 and Seq-GFP-H6 was 
analyzed by measuring fluorescence emission after incubation in different media. R9-
GFP-H6 was diluted, in triplicate, in either human serum (Sigma, ref: S2257-5ML, final 
concentration of 0.23 µg/µl) or in human and mouse plasma (final concentration of 0.11 
µg/µl). GFP-H6, Ang-GFP-H6 and Seq-GFP-H6 were also diluted, in duplicate, in the 
same media, at final concentrations of 0.23, 0.13 and 0.08 µg/µl, respectively. Human 
blood was obtained from a healthy donor in the Hospital de Sant Pau. Murine blood 
(approximately 250 µl per mouse) was obtained from the submandibular facial vein of 
five control mice (25 g) in heparinized tubes. A plasma pool sample was obtained by 
centrifugation of total blood at 600 g for 10 min at 4ºC. Right after dilution, samples 
were harvested (time 0) and its fluorescence signal was taken as the initial reference 
value (100 %). Proteins were further incubated (at 37ºC, in agitation) and samples 
were taken, at different time points, up to 22 hours. Protein functional stability during 
incubations was analyzed by fluorescence determination at 510 nm in a Cary Eclipse 
fluorescence spectrophotometer (Variant, Inc., Palo Alto, C.A) using an excitation 
wavelength of 450 nm. 
 
Dynamic light scattering 
Volume size distribution of nanoparticles and monomeric protein versions were 
measured using a dynamic light scattering (DLS) analyzer at the wavelength of 633 
nm, combined with non-invasive backscatter technology (NIBS) (Zetasizer Nano ZS, 
Malvern Instruments Limited, Malvern, U.K.). Samples were measured at 20ºC. DLS 
measurements of solvents were used as controls. The measurements were performed 
in triplicate. 
 
Fluorescence emission spectra determination 
Nanoparticles fluorescence emission spectra from 500 nm to 540 nm was determined 
by a Cari Eclipse fluorescence spectrophotometer (Variant, Inc., Palo Alto, C.A) using 
an excitation wavelength of 450nm. 
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Transmission electron microscopy (TEM) 
Droplets of each protein sample (5 µl, 0.150 mg/ml) were deposited in duplicate onto 
carbon-coated copper grids for 2 min, and excess specimen was then withdrawn. A set 
of samples was submitted to negative staining with uranyl acetate, whereas the other 
set was rotary shadowed by evaporation of atomized platinum-carbon at an angle of 
25º. Samples were observed with a Jeol 1400 transmission electron microscope 
(TEM), equipped with a CCD Gatan ES1000W Erlangshen camera. 
 
Cryo transmission electron microscopy (CryoTEM) 
Drops of protein solutions (3 µl) were deposited on Quantifoil R 1.2/1.3 grids and 
blotted to eliminate the excess of sample. Then, grids were plunged in liquid ethane in 
a Leica EM CPC, placed in a Gatan cryo-transfer specimen holder and observed in a 
Jeol JEM 2011 transmission electron microscope operating at 200 kV and equipped 
with a CCD Gatan 895 USC 4000 camera. 
 
Field Emission Scanning Electron Microscopy (FESEM) 
To characterize the native morphology and distribution of protein nanoparticles, 5 µl of 
protein solution samples were deposited into a silicon substrate, and excess of material 
was then removed. Samples were air dried and observed without coating in a FESEM 
Zeiss Merlin operating at 2 kV. Images were acquired with a high resolution in-lens 
secondary electron detector. Image J 1.46n software was used for nanoparticle size 
distribution analysis in FESEM images. 
 
Atomic force microscopy 
Atomic force microscopy (AFM) analyses were performed in liquid with a commercial 
atomic force microscope (PicoSPM 5100 from Molecular Imaging Agilent Technologies, 
Inc., Santa Clara, CA, USA) operating in acoustic mode. R9-GFP-H6 in 20 mM Tris 
buffer pH 7.5 + 5 % dextrose (4 µg/µl, 20 µl) was dropped onto a freshly cleaved mica 
surface and imaged in liquid. T22-GFP-H6 in sodium bicarbonate 1.4 % buffer pH 7.4, 
(4.3 µg/µl, 50 µl) were dropped onto a freshly cleaved mica surface and imaged in 
liquid. For the acoustic mode measurements, a silicon (Applied NanoStructures, Inc.) 
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tip, with a radius of 10 nm, a nominal spring constant of 0.6–3.7 N/m and a resonance 
frequency of 43-81 kHz was used. 
 
Size exclusion chromatography 
The molecular weight distribution of protein nanoparticles was determined by size 
exclusion chromatography after injection of 100 µl samples in a previously calibrated 
Superdex200 10/300 GL (Tricorn) column (GE Healthcare). 
 
Animals and administration regime 
 
Five-week-old female Swiss nu/nu mice weighing between 18 and 20 g (Charles River, 
L-Abreslle, France), maintained in SPF conditions, were used for in vivo studies. All the 
in vivo procedures were approved by the Hospital de Sant Pau Animal Ethics 
Committee. We assessed, stability, biodistribution and renal clearance of protein 
constructs 2 hours after i.v. administration of 500 µg/mouse (n=3 mice). The control 
mice (n=3) were administered i.v. in the appropriate buffer (20 mM Tris, 5 % dextrose  
pH 7.5 for R9-GFP-H6, 20 mM Tris, 500 mM NaCl pH 7.4 for T22-GFP-H6 and 166 
mM NaC03H pH 7.5 for Seq- and Ang-empowered constructs). We also assessed the 
stability and renal clearance of T22-IRFP-H6 dissolved in high salt carbonate buffer (+) 
or low salt carbonate buffer (-) by i.v. administration of 50 µg/mouse (n=3 mice), 24 
hours post-administration. Control mice were administered i.v. with the same buffer. 
The animal model for metastatic colorectal cancer has been described in detail 
elsewhere.19 
 
 
Biodistribution of nanoparticles in mice 
 
At 2 hours post administration, mice were anesthetised with isofluorane and whole-
body fluorescence was monitored using the IVIS® Spectrum equipment (Xenogen, 
France). Subsequently, mice blood was collected and necropsy was performed and all 
organs were removed and placed individually into wells to determine GFP or IRFP 
fluorescence in an IVIS® Spectrum. Then, these organs were collected, fixed in 4 % 
formaldehyde in phosphate buffer for 24 hours and finally embedded in paraffin for 
histological and immunohistochemical evaluation. Nanoparticle biodistribution in blood 
was determined after centrifugation using a ficoll gradient. In the resulting blood 
fractions, we registered GFP-derived fluorescence using an IVIS Spectrum. In all 
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cases, the fluorescence signal was digitalized and after subtracting the 
autofluorescence, it was displayed as a pseudocolor overlay and expressed in terms of 
Radiant efficiency for each protein group (control or experimental), dose and time. To 
calculate half-life of elimination and the elimination rate constant (kel), GFP 
fluorescence signal was recorded in plasma at time 0, 1, 2, 4, 8 hours after a single 
200 µg intravenous dose of R9-GFP-H6 or of T22-GFP-H6.  
 
 
Histopathology and inmunohistochemistry for GFP-His-tag proteins 
 
Four-micrometer-thick sections were stained with haematoxylin-eosin (H&E) and a 
complete histopathological analysis was performed by two independent observers.  In 
addition, a quantitation of the number of dead cells, as measured determining apoptotic 
bodies, in spleen, lung liver, kidney and brain tissues were counted in ten 40x 
microscopic fields. The presence and location of the GFP-His tagged proteins in tissue 
sections were demonstrated by inmunohistochemistry. Paraffin-embedded tissue 
sections (4 µm) were de-paraffinized, re-hydrated and washed in PBS-T. Antigen 
retrieval was performed by citrate buffer at 120ºC. After quenching peroxidase activity 
by incubating the slides in 3 % H2O2 for 10 min, the slides were washed in PBS-T. 
Slides were incubated 30 min with a primary antibody against GFP (1:100; St Cruz 
Biotechnology, Inc. Santa Cruz, CA, USA) or Histidine (1:1000; GE Healthcarhe, UK), 
washed in PBS-T and incubated with the secondary horseradish peroxidase (HRP) 
conjugated antibody for 30 min at room temperature. The antibody interaction was then 
visualized using the chromogenic detection, in which the HRP cleaved the DAB 
substrate (DAKO, Denmark) to produce a brown precipitate at the location of the 
protein. Finally sections were counterstained with haematoxylin, dehydrated with 
decreasing percentages of ethanol (100-95-70-50 %) and mounted using DPX 
mounting medium. Representative pictures were taken using Cell^B software (Olympus 
Soft Imaging v 3.3, Japan) at 400 x magnification.  
 
Molecular modeling 
Models of R9-GFP-H6 monomers were built using Modeller 9v2 (24) and docked using 
HADDOCK v 2.0,40 enforcing C5 symmetry and using N-terminal arginine residues as 
the active residues (Figure 4). The models were generated using the same protocols 
previously described.18 The energetics of the models were analysed with FoldX using 
the function AnalyseComplex.41  
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Figure 1. In vitro assembling of protein-only nanoparticles. A) Schematic 
representation of all protein constructs used in the study. Precise amino acid 
sequences of R9, T22, Ang (Angiopep-2) and Seq (Seq-1) have been given 
elsewhere.18,19 L is a linker peptide commonly used in phage display (GGSSRSS). 42 
The molecular masses (MM) of proteins were determined by mass spectroscopy and 
they were coincident with predicted values.  B) Size of protein complexes formed by 
distinct GFP variants, measured by DLS in representative experiments. Peak and 
polydispersion index (PDI) are shown for each plot. C) TEM images of protein 
nanoparticles upon purification from producing bacteria. D) AFM images of randomly 
selected nanoparticles and topography cross-sections of isolated entities. 
Measurements have been done in liquid with a tip radius of 10 nm. Then, the width (but 
not the high) of the particles is inherently overestimated. 
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Figure 2. Stability and biodistribution of protein constructs. A) GFP signal registered ex 
vivo in mouse spleen, lung, heart, liver sections and kidneys 2 hours after i.v. 
administration of 500 µg of each protein or buffer alone. B) Quantitative determination 
of fluorescence in analysed kidneys expressed as the total radiant efficiency 
(ph/sec/cm2/sr/µW/cm2) of right and left kidneys for each mouse. The slight variations 
found when comparing proteins could be due to differences in the specific 
fluorescence, as protein sizes are rather similar (Figure 1). C) Imnunohistochemical 
anti-GFP detection of the administered proteins in the renal tissue, which is only 
observed if the small size (< 7 nm) of the administered material determines its filtration 
and accumulation in the renal glomeruli while being excreted (400 x magnification). 
Arrowheads show high density of haematoxylin stained nuclei (blue) corresponding to 
cells in the renal tissue, including glomerular cells. Note the absence of GFP staining in 
animals administered with R9- and T22-containing proteins, and the presence of signal 
when Ang- and Seq-derived proteins were administered (brown staining). D) 
Pharmacokinetics of R9-GFP-H6 and T22-GFP-H6 after a 200 µg intravenous bolus 
administration. GFP fluorescence was recorded in plasma obtained after blood 
centrifugation at time 0, 1, 2, 4, 8 hours. The elimination rate constant (Kel), and half-
life of elimination (t1/2), were calculated using a one-compartment model and a semi-
log plot of plasma concentration versus time curve (see Supplemental Table 1). R9-
GFP-H6 and T22-GFP-H6 showed a fast distribution in the blood compartment 
followed by a slow half-life of recirculation in blood. 
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Figure 3. Stability and biodistribution of R9-GFP-H6. A) In vitro stability of protein R9-
GFP-H6 and control proteins GFP-H6, Ang-GFP-H6 and Seq-GFP-H6 in human 
plasma (circles), mouse plasma (triangles) and human serum (squares), monitored by 
fluorescent emission.B) In vivo whole-body recording of a representative mouse 2 
hours after i.v. administration with buffer alone, with 500 µg of GFP-H6 or R9-GFP-H6, 
showing occurrence of fluorescence in the brain. C) GFP fluorescence signal recording 
in ex vivo brain sagittal sections of a representative mouse. D) Inmunohistochemical 
detection of the protein using and anti-GFP antibody, in mouse brain sections 2 hours 
after i.v. administration of 500 µg of GFP-H6 and R9-GFP-H6 of buffer alone (400x).  
Arrows show protein accumulation in the brain parenchyma.  
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Figure 4. Structural memory of protein-only nanoparticles in vitro. A) DLS size analysis 
of T22-IRFP-H6 purified in low salt (carbonate buffer, -) and high salt (carbonate buffer 
+ 334 mM NaCl, +). Different measures are plotted to evidence robustness of data. B) 
TEM analysis of T22-IRFP-H6 purified in low salt buffer (assembled). C) DLS size 
analysis of T22-IRFP-H6 purified in low salt buffer and in which additional salt was 
added later to reach 500 mM NaCl. Alternatively, NP40 (D) and SDS (E) were added 
up to 1 %. Peak and PDI values are shown for each DLS plot. 
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Figure 5. Structural memory of protein-only nanoparticles in vivo. Mouse tumor and 
kidney sections were registered 24 hours after 50 µg i.v. administration of T22-IRFP-H6 
in either high (+, disassembled) or low (-, assembled) salt buffers. A) 
Immunohistochemical analysis of the tumor and glomeruli using an anti His-tag 
antibody (400X magnification). Insets show IRFP fluorescence signal detected ex vivo 
in tissues of a representative mouse for each group, after subtracting the 
autofluorescence. B) The total radiant efficiency (ph/sec/cm2/sr/µW/cm2) as determined 
for each group in tumour (top) and kidney (bottom).  
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Figure 6. Fine architecture of protein-only nanoparticles. A) Overlap of size exclusion 
chromatograms of different protein nanoparticles. Vertical red lines indicate the 
occurrence of nanoparticles by the position of peaks, indicating the estimated number 
of monomers that form them. B) Overlap of fluorescence emission spectra of 
assembled protein nanoparticles (T22-GFP-H6, R9-GFP-H6) compared with that of the 
monomeric control protein (GFP-H6). C) A) Wide field CryoTEM and FESEM images of 
protein nanoparticles formed by different proteins. The average size of each type of 
particle was determined by SEM and depicted. The insets show magnifications of 
single nanoparticles.  
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Figure 7. Different conformations of R9-GFP-H6 nanoparticles obtained in the docking 
process by using different configurations of overhanging R9 and H6 peptides. Models 
in the top row, were generated with HADDOCK 40 using R9 residues as active and H6 
residues as passive. Models in the bottom row were generated declaring only R9 
residues as active. The energetics governing protein-protein interactions in each of 
these models are given in Table 1. 
 
 
 
 
Table 1. Summary of energetics governing monomer-monomer interactions in the 
molecular models depicted in Figure 4.  
 
   
Model ª 
Hydrogen 
bond b 
Van der 
Waals b 
Electrostatics 
b 
UP 1 -47,34 -65 -21,56 
UP 2 -44,97 -57,16 -6,61 
UP 3 -29,13 -42,38 -7,33 
UP 4 -31,6 -38,18 -10,85 
    
DOWN 1 -26,45 -30,56 2,86 
DOWN 2 -23,13 -25,79 -4,6 
DOWN 3 -12,64 -20,78 1,02 
DOWN 4 -7,57 -11,83 12,21 
 
  
 
ª Models refer to those depicted in Figure 7, in top and bottom rows, numbered from left to right. 
 
b
 Values were calculated with FoldX and are given in kcal/mol.   
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